tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Cacciarelli TV et al. An analysis of pretransplantation variables associated with long-term allograft outcome in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. 1999 Transplantation pmid:10507484
Burroughs TE et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. 2007 Transplantation pmid:17452891
Vincenti F A decade of progress in kidney transplantation. 2004 Transplantation pmid:15201687
Burke GW et al. Advances in pancreas transplantation. 2004 Transplantation pmid:15201688
Pfitzmann R et al. Mycophenolatemofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. 2003 Transplantation pmid:12865798
Moss MC et al. Lithium use for bipolar disorder post renal transplant: is mood stabilization without toxicity possible? 2014 Transplantation pmid:24492429
Fridell JA et al. Steroid withdrawal for pancreas after kidney transplantation in recipients on maintenance prednisone immunosuppression. 2006 Transplantation pmid:16906038
Narayanan M et al. Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression. 2013 Transplantation pmid:23423268
Moffatt SD et al. Potential for improved therapeutic index of FK506 in liposomal formulation demonstrated in a mouse cardiac allograft model. 1999 Transplantation pmid:10342309
Yoshihara S et al. Successful treatment of life-threatening human herpesvirus-6 encephalitis with donor lymphocyte infusion in a patient who had undergone human leukocyte antigen-haploidentical nonmyeloablative stem cell transplantation. 2004 Transplantation pmid:15077022
Bierer BE et al. Mechanisms of immunosuppression by FK506. Preservation of T cell transmembrane signal transduction. 1990 Transplantation pmid:1694317
Yin DP et al. Lewis rat pancreas, but not cardiac xenografts, are resistant to anti-gal antibody mediated hyperacute rejection. 2001 Transplantation pmid:11391223
Krentz AJ Posttransplantation Diabetes Mellitus in FK-506-Treated Renal Transplant Recipients: Analysis of Incidence and Risk Factors. Transplantation 2001; 72: 1655. 2001 Transplantation pmid:11726815
Bruce DS et al. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients. 2001 Transplantation pmid:11726823
Sanchez-Campos S et al. Cholestasis and alterations of glutathione metabolism induced by tacrolimus (FK506) in the rat. 1998 Transplantation pmid:9679826
Egeland EJ et al. High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation. 2017 Transplantation pmid:28452920
Hsiau M et al. Monitoring nonadherence and acute rejection with variation in blood immunosuppressant levels in pediatric renal transplantation. 2011 Transplantation pmid:21857278
Yates CJ et al. Screening for new-onset diabetes after kidney transplantation: limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin. 2013 Transplantation pmid:23902993
Kaplan B et al. Frequency of hyperkalemia in recipients of simultaneous pancreas and kidney transplants with bladder drainage. 1996 Transplantation pmid:8900321
Bronster DJ et al. Tacrolimus-associated mutism after orthotopic liver transplantation. 2000 Transplantation pmid:11014653
Lufft V et al. Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. 1996 Transplantation pmid:8779695
Yu S et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. 2006 Transplantation pmid:16421475
Muraki T et al. Effects of cyclosporine and FK506 on in vitro high shear-induced platelet reactivity in rat and human non-anticoagulated blood. 1998 Transplantation pmid:9583878
Kadry Z et al. Kaposi's sarcoma in liver transplant recipients on FK506. 1998 Transplantation pmid:9583882
Ho ET et al. Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: a systematic review. 2013 Transplantation pmid:23542469
Shapiro R et al. Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. 2008 Transplantation pmid:18431232
Porrini E et al. Prediabetes in patients receiving tacrolimus in the first year after kidney transplantation: a prospective and multicenter study. 2008 Transplantation pmid:18431233
Veroux M et al. Impact of conversion to a once daily tacrolimus-based regimen in kidney transplant recipients with gastrointestinal complications. 2012 Transplantation pmid:22298033
Inoue T et al. Lesser reduction in bone mineral density by the immunosuppressant, FK506, compared with cyclosporine in rats. 2000 Transplantation pmid:11003356
Holt S and Moore K Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. 2002 Transplantation pmid:11907407
Yang H et al. Liposomal encapsulation significantly enchances the immunosuppressive effect of tacrolimus in a discordant islet xenotransplant model. 2002 Transplantation pmid:11907415
St A Nunes FA and Lucey MR Searching for a balance when applying immunosuppression after liver transplantation. 2001 Transplantation pmid:11258425
Podesser BK et al. Comparison of low and high initial tacrolimus dosing in primary heart transplant recipients: a prospective European multicenter study. 2005 Transplantation pmid:15714171
Steinmüller TM et al. The effect of FK506 versus cyclosporine on glucose and lipid metabolism--a randomized trial. 1994 Transplantation pmid:7524203
Sonoda T et al. Outcome of 3 years of immunosuppression with tacrolimus in more than 1,000 renal transplant recipients in japan. 2003 Transplantation pmid:12548123
Roberti I et al. Evidence that the systematic analysis of bile cytology permits monitoring of hepatic allograft rejection. 1992 Transplantation pmid:1384182
Guthery SL et al. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. 2003 Transplantation pmid:12698085
Jain A et al. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis. 2003 Transplantation pmid:12698091
Peng Y et al. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. 2013 Transplantation pmid:23263506
Murase N et al. Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. 1993 Transplantation pmid:7678353
Chan L et al. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. 2010 Transplantation pmid:20517177
Manzanares C et al. Influence of hepatitis C virus infection on FK 506 blood levels in renal transplant patients. 1998 Transplant. Proc. pmid:9636513
Takahashi K et al. Safety and efficacy of once-daily modified-release tacrolimus in kidney transplant recipients: interim analysis of multicenter postmarketing surveillance in Japan. 2014 Transplant. Proc. pmid:24655975
Frei U and Wagner K Renal function in liver transplant patients receiving FK506 or cyclosporin A immunosuppressive therapy. 1994 Transplant. Proc. pmid:7527963
Park K et al. Efficacy of tacrolimus in primary kidney transplant patients: multicenter, open-label prospective study. 2000 Transplant. Proc. pmid:11119901
Lane BC et al. Evaluation of calcineurin's role in the immunosuppressive activity of FK 506, related macrolactams, and cyclosporine. 1993 Transplant. Proc. pmid:7679829
Christians U et al. High performance liquid chromatography/mass spectrometry of FK 506 and its metabolites in blood, bile, and urine of liver grafted patients. 1991 Transplant. Proc. pmid:1721262
Regazzi MB et al. Interaction between FK 506 and diltiazem in an animal model. 1996 Transplant. Proc. pmid:8623215
Cadoff EM et al. Assay of FK 506 in plasma. 1990 Transplant. Proc. pmid:1689898
Rahamimov R et al. Rejection rate in living donor kidney transplantation with and without basiliximab in tacrolimus/mycophenolate mofetil-based protocol. 2003 Transplant. Proc. pmid:12644082
Sgrosso JL et al. Histopathological findings in heart transplant patients under tacrolimus-mycophenolate mofetil versus cyclosporine microemulsion-azathioprine. 2002 Transplant. Proc. pmid:11959214
Rodrigo E et al. High initial blood levels of tacrolimus in overweight renal transplant recipients. 2005 Transplant. Proc. pmid:15866635
Rudich SM et al. Immunosuppression using tacrolimus, mycophenolate, and prednisone following orthotopic liver transplantation: a single-center experience. 1998 Transplant. Proc. pmid:9636574
Martínez-Castelao A et al. Arterial elasticity measurement in renal transplant patients under anticalcineurin immunosuppression. 2005 Transplant. Proc. pmid:16386539
Sessa A et al. Immunosuppressive agents and metabolic factors of cardiovascular risk in renal transplant recipients. 2009 Transplant. Proc. pmid:19460510
Armenta Bautista A et al. Renal Transplantation in Second-Level Private Hospitals in the State of Mexico. 2018 Transplant. Proc. pmid:29579825
Imamura M et al. FK 506 inhibits severe graft-versus-host disease without mediating cytokine balance and/or cytotoxic molecules. 2000 Transplant. Proc. pmid:11120238
Forsythe J Tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. The European Multicentre Tacrolimus/MMF Study Group. 1999 Transplant. Proc. pmid:10576049
Ullman KS et al. Site of action of cyclosporine and FK 506 in the pathways of communication between the T-lymphocyte antigen receptor and the early activation genes. 1991 Transplant. Proc. pmid:1721294
Yang S et al. Characteristics of long-term immunosuppressive therapy in Chinese pediatric renal transplant patients: a single-center experience. 2009 Transplant. Proc. pmid:20005361
Hohage H et al. Cyclosporine and tacrolimus: influence on cardiovascular risk factors. 2005 Transplant. Proc. pmid:15848615
Nassar CA et al. Effects of long-term FK 506 therapy on the alveolar bone and cementum of rats. 2009 Transplant. Proc. pmid:19545747
Kurnatowska I et al. Tacrolimus dose and blood concentration variability in kidney transplant recipients undergoing conversion from twice daily to once daily modified release tacrolimus. 2011 Transplant. Proc. pmid:21996199
Moscicka M et al. The effect of cyclosporine and tacrolimus on indigenous bacterial flora in human skin grafts. 2003 Transplant. Proc. pmid:14529942
Ricordi C et al. Effect of FK 506 on human pancreatic islets following renal subcapsular transplantation in diabetic nude mice. 1992 Transplant. Proc. pmid:1376512
Kim HC et al. Primary immunosuppression with tacrolimus in renal transplantation: a single center experience. 2003 Transplant. Proc. pmid:12591370
Cooper MH et al. Evaluation of the influence of FK 506, rapamycin, and cyclosporine on processing and presentation of particulate antigen by macrophages: assessment of a drug "carry-over" effect. 1991 Transplant. Proc. pmid:1721326
Chen JW et al. Ten-year results of a randomised prospective study of FK506 versus cyclosporine in management of primary orthotopic liver transplantation. 2002 Transplant. Proc. pmid:12176460
Costa A et al. Small bowel myoelectrical activity after transplantation in pigs: motility versus ACR score. 1997 Transplant. Proc. pmid:9142281
Aktürk S et al. Average Tacrolimus Trough Level in the First Month After Transplantation May Predict Acute Rejection. 2017 Transplant. Proc. pmid:28340806
Sakamoto K et al. Sodium-losing nephropathy and distal tubular damage of transplant kidneys with FK506 administration. 1995 Transplant. Proc. pmid:7533434
Armitage JM et al. The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation. 1991 Transplant. Proc. pmid:1721358
Nalesnik MA et al. Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population. 1991 Transplant. Proc. pmid:1703335
Hung CM et al. Tacrolimus to rescue refractory hepatic allograft rejection: a collaborative study in Taiwan. 1998 Transplant. Proc. pmid:9838572
Miller J Tacrolimus and mycophenolate mofetil in renal transplant recipients: one year results of a multicenter, randomized dose ranging trial. FK506/MMF Dose-Ranging Kidney Transplant Study Group. 1999 Feb-Mar Transplant. Proc. pmid:10083106
Busuttil RW and Holt CD Tacrolimus (FK506) is superior to cyclosporine in liver transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123119
Namieno T and Uchino J Comparative study of the effects of cyclosporine and FK 506 on rat hepatocytes cocultured with nonparenchymal liver cells. 1996 Transplant. Proc. pmid:8908147
Arita C et al. Effect of FK 506 (FR 900506) on collagen arthritis in rats: a preliminary report. 1989 Transplant. Proc. pmid:2468206
Tze WJ et al. Effect of FK 506 on glucose metabolism and insulin secretion in normal rats. 1991 Transplant. Proc. pmid:1721391
Bilbao I et al. Comparison between tacrolimus and neoral cyclosporine administered by oral route in liver transplantation. 2001 Transplant. Proc. pmid:11377472
van Duijnhoven EM et al. Evidence that fasting does not significantly affect trough levels of tacrolimus in stable renal transplant recipients. 2002 Transplant. Proc. pmid:12176552
Weinbroum AA et al. Lack of cumulative effect of tacrolimus and low flow on a rat isolated liver. 2001 Transplant. Proc. pmid:11543812
Zuckermann A et al. Benefit of mycophenolate mofetil in patients with cyclosporine A-induced nephropathy after lung transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083518
Ohdan H et al. Prolongation of hamster-to-rat liver xenograft survival by donor bone marrow augmentation. 1997 Feb-Mar Transplant. Proc. pmid:9123589
Maass E et al. Decrease in serum tacrolimus level and rise in serum creatinine under late addition of cinacalcet in a renal transplant recipient with hyperparathyroidism: a case report. 2007 Transplant. Proc. pmid:18089410
Mabuchi M et al. Insulin-like growth factor-I enhances choleretic action of FK506 in rats. 2003 Transplant. Proc. pmid:12826230
McLaughlin GE et al. Use of phenobarbital in the management of acute tacrolimus toxicity: a case report. 2000 Transplant. Proc. pmid:10812158
Lo A et al. Observations on the use of sirolimus and tacrolimus in high-risk renal transplant recipients. 2003 Transplant. Proc. pmid:12742477
El-Sabrout R et al. Rejection-free protocol using sirolimus-tacrolimus combination for pediatric renal transplant recipients. 2002 Transplant. Proc. pmid:12176636
Wu M et al. Cyclosporine and tacrolimus alter renin-angiotesin system in mouse medullary-thick ascending limb cultured cells. 2001 Feb-Mar Transplant. Proc. pmid:11267198
Halloran PF et al. Calcineurin and the biological effect of cyclosporine and tacrolimus. 1998 Transplant. Proc. pmid:9723430
Walgenbach KJ et al. Upregulation of basic fibroblast growth factor during chronic rejection of rat intestinal allografts and its downregulation by FK 506. 1998 Transplant. Proc. pmid:9745501
Murio JE et al. Compassionate use of FK 506 in liver transplantation. 1995 Transplant. Proc. pmid:7544501
Kim YE and Eun SC Effect of FK506 ointment (Protopic) on rat skin allograft model. 2014 Transplant. Proc. pmid:24815165
Sainsbury TS et al. Differential effects of FK 506 and cyclosporine on hair regrowth in the DEBR model of alopecia areata. 1991 Transplant. Proc. pmid:1721453
Shingaki S et al. Graft-versus-host Disease-free, Relapse-free Survival After HLA-identical Sibling Peripheral Blood Stem Cell Transplantation With Tacrolimus-based Graft-versus-host Disease Prophylaxis in Japanese Patients. Transplant. Proc. pmid:29407317
Umbro I et al. Long-term interleukin-2 assessment after conversion from a twice-daily to once-daily tacrolimus regimen in stable kidney recipients. 2012 Transplant. Proc. pmid:22974867
Tariciotti L et al. Everolimus and Advagraf Ab Initio in Combined Liver and Kidney Transplant With Donor-Specific Antibodies: A Case Report. 2016 Transplant. Proc. pmid:27932158
Miyagawa S et al. Mechanism of unresponsiveness in rats induced by a short course of FK 506 or CyA. 1991 Transplant. Proc. pmid:1703687
Pridöhl O et al. Low-dose immunosuppression with FK 506 and sirolimus after liver transplantation: 1-year results. 2001 Nov-Dec Transplant. Proc. pmid:11750384